Today: 24 December 2025
Subscribe
Browse Category

NASDAQ:QURE News 24 September 2025 - 16 December 2025

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

Dec. 16, 2025 — uniQure N.V. (NASDAQ: QURE) is back in the spotlight Tuesday after a notable extended-hours rebound. The gene therapy developer’s shares were highlighted among top pre-market gainers, rising about 15% to roughly $23.50 in early trading, following
16 December 2025
 ·  ·  ·  ·  · 
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Key facts (quick read) In‑depth report 1) Huntington’s disease, in plain English What it is. HD is a progressive brain disorder that typically begins in mid‑adulthood, causing a mix of movement (chorea, dystonia), cognitive (processing speed, executive function) and psychiatric symptoms
26 September 2025
 ·  ·  ·  ·  ·  ·  · 
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

Stock Performance and Valuation Metrics uniQure’s stock performance in 2025 has been remarkably strong, capped by the explosive move on Sep. 24 after the Huntington’s data release. Prior to the announcement, QURE was trading in the mid-teens (around ~$14–$15) ts2.tech – already up
24 September 2025
 ·  ·  ·  ·  · 
Go toTop